Pantoprazole, azithromycin and tinidazole: short duration triple therapy for eradication of Helicobacter pylori infection
Article first published online: 2 JAN 2002
Alimentary Pharmacology & Therapeutics
Volume 14, Issue 12, pages 1613–1617, December 2000
How to Cite
Calabrese, C., Di Febo, G., Areni, A., Scialpi, C., Biasco, G. and Miglioli, M. (2000), Pantoprazole, azithromycin and tinidazole: short duration triple therapy for eradication of Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics, 14: 1613–1617. doi: 10.1046/j.1365-2036.2000.00879.x
- Issue published online: 2 JAN 2002
- Article first published online: 2 JAN 2002
Azithromycin is an acid-stable macrolide that achieves remarkably high concentrations in gastric tissue, persisting above the MIC90 for Helicobacter pylori over a period of 5-days, after a single 500 mg oral dose.
To evaluate and compare the efficacy, safety, and tolerability of two eradicating regimens of pantoprazole, azithromycin and tinidazole.
A total of 100 consecutive symptomatic H. pylori-positive patients received pantoprazole 40 mg b.d. for 1 week, and were randomly assigned to either azithromycin 500 mg o.m. and tinidazole 500 mg b.d. during the first 3 days (early group, n=50) or during the last 3 days of therapy with pantoprazole (late group, n=50). H. pylori status was assessed by histology and rapid urease test at entry and by histology and 13C-urea breath test 1 month after the end of the therapy.
Ninety-nine patients completed the study. H. pylori was eradicated in 86% of patients in the early group (intention-to-treat 86%) and in 88% of patients in the late group (intention-to-treat 88%).
This short triple therapy is effective for H. pylori eradication. The compliance was excellent and side-effects negligible. Moreover, the pantoprazole pre-treatment did not modify the efficacy of the therapy.